Implication of KDR Polymorphism rs2071559 on Therapeutic Outcomes and Safety of Postoperative Patients with Gastric Cancer Who Received S-1-Based Adjuvant Chemotherapy: A Real-World Exploratory Study

References

• Li Y, Zhou D, Liu Q, et al. Gene polymorphisms of m6A erasers FTO and ALKBH1 associated with susceptibility to gastric cancer. Pharmgenomics Pers Med. 2022;15:547–559. doi:10.2147/pgpm.s360912
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Chen J, Chen J, Lv X, Yang Q, Yao S. Epidermal growth factor in exhaled breath condensate as diagnostic method for non-small cell lung cancer. Technol Cancer Res Treat. 2019;18:153303381987227. doi:10.1177/1533033819872271
   Web of Science ®Google Scholar
• Wang H, Guo W, Hu Y, et al. Superiority of the 8th edition of the TNM staging system for predicting overall survival in gastric cancer: comparative analysis of the 7th and 8th editions in a monoinstitutional cohort. Mol Clin Oncol. 2018;9(4):423–431. doi:10.3892/mco.2018.1683
   PubMed Web of Science ®Google Scholar
• Han SU, Hur H, Lee HJ, et al. Surgeon quality control and standardization of D2 lymphadenectomy for gastric cancer: a prospective multicenter observational study (KLASS-02-QC). Ann Surg. 2021;273(2):315–324. doi:10.1097/sla.0000000000003883
   PubMed Web of Science ®Google Scholar
• Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(☆). Ann Oncol. 2021;32(3):368–374. doi:10.1016/j.annonc.2020.11.017
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820. doi:10.1056/NEJMoa072252
   PubMed Web of Science ®Google Scholar
• Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan clinical oncology group study (JCOG0501). Gastric Cancer. 2019;22(5):1044–1052. doi:10.1007/s10120-019-00941-z
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–221. doi:10.1016/s1470-2045(08)70035-4
   PubMed Web of Science ®Google Scholar
• Yang L, Zou S, Shu C, et al. CYP2A6 polymorphisms associate with outcomes of S-1 plus oxaliplatin chemotherapy in Chinese gastric cancer patients. Geno Prot Bioinfor. 2017;15(4):255–262. doi:10.1016/j.gpb.2016.11.004
   PubMed Web of Science ®Google Scholar
• Folkman J, Parris EE, Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186. doi:10.1056/nejm197111182852108
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen H, Lu L, et al. New insights into the role of co-receptor neuropilins in tumour angiogenesis and lymphangiogenesis and targeted therapy strategies. J Drug Target. 2021;29(2):155–167. doi:10.1080/1061186x.2020.1815210
   PubMed Web of Science ®Google Scholar
• Liu K, Ren T, Huang Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 2017;8(8):e3015. doi:10.1038/cddis.2017.422
   PubMed Web of Science ®Google Scholar
• Li Z, Wang M, Gu J, et al. Missense variants in hypoxia-induced VEGFA/VEGFR2 signaling predict the outcome of large artery atherosclerotic stroke. Cell Mol Neurobiol. 2021;41(6):1217–1225. doi:10.1007/s10571-020-00890-7
   PubMed Web of Science ®Google Scholar
• Geng N, Ding CM, Liu ZK, Song S, Hu WX. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study. Int J Clin Oncol. 2021;26(4):670–683. doi:10.1007/s10147-020-01849-w
   PubMed Web of Science ®Google Scholar
• Yan Z, Gu YY, Hu XD, et al. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. Oncol Lett. 2020;20(3):3035–3045. doi:10.3892/ol.2020.11857
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang Y, Xue W, et al. The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer. Cancer Biol Ther. 2019;20(4):497–504. doi:10.1080/15384047.2018.1537575
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–4393. doi:10.1200/jco.2011.36.5908
   PubMed Web of Science ®Google Scholar
• Bai M, Li ZG, Ba Y. Influence of KDR genetic variation on the efficacy and safety of patients with chemotherapy refractory metastatic CRC who received apatinib treatment. Int J Gen Med. 2021;14:1041–1055. doi:10.2147/ijgm.s300968
   PubMed Web of Science ®Google Scholar
• Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics. 2005;21(3):389–395. doi:10.1152/physiolgenomics.00025.2005
   PubMed Web of Science ®Google Scholar
• Zhi DB, Wang ZY, Xie T, Tu WW. Influence of GSTP-1 polymorphism on the prognosis of patients with high-grade glioma who received temozolomide plus radiotherapy adjuvant treatment. Int J Gen Med. 2021;14:10173–10183. doi:10.2147/ijgm.s328810
   PubMed Web of Science ®Google Scholar
• de Steur WO, van Amelsfoort RM, Hartgrink HH, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol. 2021;32(3):360–367. doi:10.1016/j.annonc.2020.11.004
   PubMed Web of Science ®Google Scholar
• Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective. World J Gastroenterol. 2018;24(26):2818–2832. doi:10.3748/wjg.v24.i26.2818
   PubMed Web of Science ®Google Scholar
• Kanaji S, Suzuki S, Matsuda Y, et al. Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer. Ann Gastroenterol Surg. 2018;2(6):400–405. doi:10.1002/ags3.12199
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Tsugawa H, Suzuki H. Precision medicine approaches to prevent gastric cancer. Gut Liver. 2021;15(1):3–12. doi:10.5009/gnl19257
   PubMed Web of Science ®Google Scholar
• Juarez I, Gutierrez A, Vaquero-Yuste C, et al. TGFB1 polymorphisms and TGF-β1 plasma levels identify gastric adenocarcinoma patients with lower survival rate and disseminated disease. J Cell Mol Med. 2021;25(2):774–783. doi:10.1111/jcmm.16131
   PubMed Web of Science ®Google Scholar
• Kim BS, Lee I, Yook JH, Song K, Kim BS. Association between the MUC1 rs4072037 polymorphism and risk of gastric cancer and clinical outcomes. J Gastric Cancer. 2020;20(2):127–138. doi:10.5230/jgc.2020.20.e11
   PubMed Web of Science ®Google Scholar
• Zhao X, Dai D, Li X, et al. A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer. Gastric Cancer. 2019;22(6):1121–1129. doi:10.1007/s10120-019-00962-8
   PubMed Web of Science ®Google Scholar
• Joo Kang S, Shin CM, Sung J, Kim N. Association between ALDH2 polymorphism and gastric cancer risk in terms of alcohol consumption: a meta-analysis. Alcohol Clin Exp Res. 2021;45(1):6–14. doi:10.1111/acer.14508
   PubMedGoogle Scholar
• Su J, Dai B, Yuan W, et al. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study. Cancer Chemother Pharmacol. 2020;85(5):969–978. doi:10.1007/s00280-020-04069-1
   PubMed Web of Science ®Google Scholar
• Yang J, Xu H, Guo X, et al. Pretreatment inflammatory indexes as prognostic predictors for survival in colorectal cancer patients receiving neoadjuvant chemoradiotherapy. Sci Rep. 2018;8(1):3044. doi:10.1038/s41598-018-21093-7
   PubMed Web of Science ®Google Scholar
• de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229–1254. doi:10.1007/s40262-018-0644-7
   PubMed Web of Science ®Google Scholar
• Zhuo YJ, Shi Y, Wu T. NRP-1 and KDR polymorphisms are associated with survival time in patients with advanced gastric cancer. Oncol Lett. 2019;18(5):4629–4638. doi:10.3892/ol.2019.10842
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang J, Chen Y, et al. Genetic variants of VEGF (rs201963 and rs3025039) and KDR (rs7667298, rs2305948, and rs1870377) are associated with glioma risk in a han Chinese population: a case-control study. Mol Neurobiol. 2016;53(4):2610–2618. doi:10.1007/s12035-015-9240-0
   PubMed Web of Science ®Google Scholar
• Geng N, Su J, Liu Z, et al. The influence of KDR genetic variation on the efficacy and safety of patients with advanced NSCLC receiving first-line bevacizumab plus chemotherapy regimen. Technol Cancer Res Treat. 2021;20:153303382110194. doi:10.1177/15330338211019433
   Web of Science ®Google Scholar
• Zhong M, Li N, Qiu X, et al. TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal cancer. Int J Biol Sci. 2020;16(2):272–283. doi:10.7150/ijbs.37906
   PubMed Web of Science ®Google Scholar
• Xie Y, Mansouri M, Rizk A, Berger P. Regulation of VEGFR2 trafficking and signaling by Rab GTPase-activating proteins. Sci Rep. 2019;9(1):13342. doi:10.1038/s41598-019-49646-4
   PubMedGoogle Scholar
• Schacher NM, Raaz-Schrauder D, Pasutto F, et al. Impact of single nucleotide polymorphisms in the VEGFR2 gene on endothelial cell activation under non‑uniform shear stress. Int J Mol Med. 2019;44(4):1366–1376. doi:10.3892/ijmm.2019.4301
   PubMed Web of Science ®Google Scholar
• Du Y, Chen Q, Huang L, et al. VEGFR2 and VEGF-C suppresses the epithelial-mesenchymal transition via YAP in retinal pigment epithelial cells. Curr Mol Med. 2018;18(5):273–286. doi:10.2174/1566524018666181004115304
   PubMed Web of Science ®Google Scholar
• Wang J, Taylor A, Showeil R, et al. Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Cytokine. 2014;68(2):94–100. doi:10.1016/j.cyto.2014.04.005
   PubMed Web of Science ®Google Scholar
• Hirashima Y, Yamada Y, Matsubara J, et al. Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci. 2009;100(2):310–315. doi:10.1111/j.1349-7006.2008.01020.x
   PubMed Web of Science ®Google Scholar